Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 51 to 60 of 1447 total matches.
Drugs for Gout
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
,
poorly tolerated, or contraindicated.
The Medical Letter ® Vol. 65 (1688) October 30, 2023
Table 1 ...
Drugs for gout are used to reduce the pain and
inflammation of acute flares, decrease the frequency
of exacerbations, and lower serum urate levels to
prevent recurrent flares, development of tophi, and
joint damage.
Med Lett Drugs Ther. 2023 Oct 30;65(1688):169-75 doi:10.58347/tml.2023.1688a | Show Introduction Hide Introduction
AD-Detect — A Blood Test for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
.
The Medical Letter ® Vol. 65 (1688) October 30, 2023
Letter
AD, past diagnosed brain trauma or head injury ...
AD-Detect (Quest), a blood test to evaluate
Alzheimer's disease risk, is being marketed directly
to consumers. It has not been cleared or approved
by the FDA (laboratory-developed tests like this
one currently do not need FDA authorization to be
marketed).
Med Lett Drugs Ther. 2023 Oct 30;65(1688):175-6 doi:10.58347/tml.2023.1688b | Show Introduction Hide Introduction
Influenza Vaccine for 2023-2024
The Medical Letter on Drugs and Therapeutics • Oct 16, 2023 (Issue 1687)
During the
The Medical Letter ® Vol. 65 (1687) October 16, 202
vaccination was associated with a 52 ...
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2023-2024 season
are listed in Table 2.
Med Lett Drugs Ther. 2023 Oct 16;65(1687):161-6 doi:10.58347/tml.2023.1687a | Show Introduction Hide Introduction
Nalmefene Nasal Spray (Opvee) for Reversal of Opioid Overdose
The Medical Letter on Drugs and Therapeutics • Oct 16, 2023 (Issue 1687)
Elimination Primarily in urine as metabolites
Half-life 11.4 hours
The Medical Letter ® Vol. 65 (1687 ...
The FDA has approved an intranasal formulation of
the opioid antagonist nalmefene (Opvee – Indivior) for
emergency treatment of known or suspected opioid
overdose in persons ≥12 years old. Nalmefene, which
is available by prescription, is the second opioid
antagonist to become available as a nasal spray
for this indication; the first was naloxone, which is
now available for sale over the counter (Narcan, and
generic). Other nasal spray formulations of naloxone
and injectable formulations of nalmefene and
naloxone are available by prescription (see Table 2).
Med Lett Drugs Ther. 2023 Oct 16;65(1687):166-7 doi:10.58347/tml.2023.1687b | Show Introduction Hide Introduction
Quizartinib (Vanflyta) for Acute Myeloid Leukemia (online only)
The Medical Letter on Drugs and Therapeutics • Oct 16, 2023 (Issue 1687)
e170
The Medical Letter ® Vol. 65 Published online October 16, 2023
1. J-S Ahn and H-J Kim. FLT3 ...
The FDA has approved the oral kinase inhibitor
quizartinib (Vanflyta – Daiichi Sankyo) for use
in combination with standard cytarabine and
anthracycline induction and cytarabine consolidation,
and as maintenance monotherapy following
consolidation chemotherapy in adults with FLT3
internal tandem duplication (ITD)-positive, newly-diagnosed
acute myeloid leukemia (AML).
Med Lett Drugs Ther. 2023 Oct 16;65(1687):e169-70 doi:10.58347/tml.2023.1687d | Show Introduction Hide Introduction
Two Vaccines (Arexvy and Abrysvo) for Prevention of RSV Disease
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
.
The Medical Letter ® Vol. 65 (1686) October 2, 2023 nirsevimab Beyfortus Arexvy Abrysvo RSV Synagis ...
Two recombinant vaccines, Arexvy (GSK) and
Abrysvo (Pfizer), have been approved by the FDA for
prevention of lower respiratory tract disease (LRTD)
caused by respiratory syncytial virus (RSV) in adults
≥60 years old. They are the first RSV vaccines to be
approved in the US. Abrysvo is also approved for
use in pregnant women at 32-36 weeks' gestation
to prevent LRTD caused by RSV in their infants from
birth through 6 months of age.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):155-6 doi:10.58347/tml.2023.1686a | Show Introduction Hide Introduction
Lodoco: Low-Dose Colchicine for Cardiovascular Event Prevention
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
.
The Medical Letter ® Vol. 65 (1686) October 2, 2023Medical
Letter Lodoco colchicine Colcrys gout Myinfla ...
Colchicine (Colcrys, and others), which has been
available in the US for decades for prophylaxis
and treatment of gout flares and other indications
in oral formulations that contain 0.6 mg of the
drug, has now been approved in 0.5-mg tablets as
Lodoco (Agepha) to reduce the risk of myocardial
infarction (MI), stroke, coronary revascularization,
and cardiovascular death in adults with established
atherosclerotic disease or multiple risk factors for
cardiovascular disease.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):156-7 doi:10.58347/tml.2023.1686b | Show Introduction Hide Introduction
Valoctocogene Roxaparvovec (Roctavian) – A Gene Therapy for Severe Hemophilia A
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
to patients receiving
immunosuppressive therapy.
The Medical Letter ® Vol. 65 (1686) October 2, 202358 ...
Valoctocogene roxaparvovec-rvox (Roctavian –
Biomarin), an adeno-associated virus (AAV) vector-based
gene therapy, has been approved by the FDA
for one-time treatment of severe hemophilia A
in adults without pre-existing antibodies to AAV
serotype 5. It is the first gene therapy to be approved
in the US for treatment of hemophilia A.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):157-8 doi:10.58347/tml.2023.1686c | Show Introduction Hide Introduction
Delandistrogene Moxeparvovec (Elevidys) for Duchenne Muscular Dystrophy
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
.
The Medical Letter ® Vol. 65 (1686) October 2, 2023 Duchenne muscular dystrophy delandistrogene moxeparvovec ...
Delandistrogene moxeparvovec-rokl (Elevidys –
Sarepta), an adeno-associated virus (AAV) vector-based
gene therapy, has received accelerated
approval from the FDA for treatment of ambulatory
children 4-5 years old with Duchenne muscular
dystrophy (DMD) who have a confirmed mutation in
the dystrophin gene. It is the first gene therapy to be
approved in the US for treatment of DMD. Accelerated
approval was based on expression of microdystrophin
in skeletal muscle, a surrogate endpoint.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):159-60 doi:10.58347/tml.2023.1686d | Show Introduction Hide Introduction
Nirsevimab (Beyfortus) for Prevention of Severe RSV Disease in Young Children
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023 (Issue 1685)
randomized to receive nirsevimab 50 mg (5 kg) IM or placebo.7
The Medical Letter ® Vol ...
The FDA has approved nirsevimab-alip (Beyfortus –
AstraZeneca/Sanofi), a long-acting monoclonal
antibody, for the prevention of respiratory syncytial
virus (RSV) lower respiratory tract disease in
neonates and infants born during or entering their
first RSV season, and in children ≤24 months old who
are at increased risk for severe RSV disease through
their second RSV season. Nirsevimab is the first drug
to be approved for protection of all infants during
their first RSV season.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):145-7 doi:10.58347/tml.2023.1685a | Show Introduction Hide Introduction